Published in Childs Nerv Syst on September 20, 2016
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med (2010) 8.28
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol (2014) 5.21
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol (2006) 4.24
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg (1997) 2.23
Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Support Care Cancer (2011) 2.02
Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol (2011) 1.90
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol (2012) 1.88
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol (2012) 1.88
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer (2007) 1.81
Targeted therapy for BRAFV600E malignant astrocytoma. Clin Cancer Res (2011) 1.79
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res (2011) 1.49
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 1.48
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol (1997) 1.47
A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol (2010) 1.46
High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol (2002) 1.45
Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol (1993) 1.32
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer (2009) 1.29
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol (2014) 1.28
Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol (2013) 1.25
Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol (2012) 1.14
Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery (2011) 1.12
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res (2011) 1.10
BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol (2013) 1.08
Temozolomide in children with progressive low-grade glioma. Neuro Oncol (2007) 1.05
Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer (2012) 1.03
Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Front Oncol (2015) 1.02
A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol (2010) 1.02
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol (2003) 1.01
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol (2013) 0.98
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol (2010) 0.96
Brain stem tumors in children and adolescents: single institutional experience. Childs Nerv Syst (2013) 0.94
Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am (2013) 0.94
Radiotherapy in pediatric pilocytic astrocytomas. A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol (2013) 0.92
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer (2012) 0.92
Natural history and management of low-grade glioma in NF-1 children. J Neurooncol (2010) 0.89
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer (2014) 0.89
Using different schedules of Temozolomide to treat low grade gliomas: systematic review of their efficacy and toxicity. J Neurooncol (2011) 0.89
Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer (2007) 0.88
Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer (2014) 0.88
Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: report from the HIT-LGG 1996 trial. Pediatr Blood Cancer (2011) 0.88
Advances in the management of low-grade gliomas. Curr Oncol Rep (2014) 0.86
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. J Transl Med (2014) 0.84
New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res (2013) 0.84
Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Pediatr Blood Cancer (2013) 0.81
Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. Future Oncol (2016) 0.79
Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol (2016) 0.79
Low Grade Gliomas in Children. J Child Neurol (2015) 0.79
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol (2014) 0.78
Late Effects After Radiotherapy for Childhood Low-grade Glioma. Am J Clin Oncol (2016) 0.77
Outcomes of pediatric low-grade gliomas treated with radiation therapy: a single-institution study. J Pediatr Hematol Oncol (2014) 0.77
Health related quality of life (HRQOL) in long-term survivors of pediatric low grade gliomas (LGGs). J Neurooncol (2014) 0.77
Metastatic Low-Grade Gliomas in Children: 20 Years' Experience at St. Jude Children's Research Hospital. Pediatr Blood Cancer (2015) 0.76
Prognostic factors and survival patterns in pediatric low-grade gliomas over 4 decades. J Pediatr Hematol Oncol (2013) 0.76
The Changing Landscape of Pediatric Low-Grade Gliomas: Clinical Challenges and Emerging Therapies. Neuropediatrics (2016) 0.76
Review of low-grade gliomas in children--evolving molecular era and therapeutic insights. Childs Nerv Syst (2015) 0.76
Sustained response to weekly vinblastine in 2 children with pilomyxoid astrocytoma associated with diencephalic syndrome. J Pediatr Hematol Oncol (2013) 0.75